ASCENTAGE PHARMA GROUP INTERNATIONAL Funds and ETFs Ascentage Pharma Group International
Equities
6855
KYG0519B1023
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.62 HKD | +1.85% |
|
+12.23% | -35.46% |
| Apr. 25 | Ascentage Pharma to Present Four Studies at US Oncology Meet | MT |
| Apr. 09 | Ascentage Pharma Chairman Boosts Stake in Firm | MT |
ETFs positioned on Ascentage Pharma Group International
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.84% | 4 M€ | -27.92% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.01% | 117 M€ | +1.11% | - | |
| 0.00% | 7 M€ | +1.95% | - | |
| 0.00% | 34 M€ | +2.14% | - |
Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
16.31
CNY
Average target price
27.24
CNY
Spread / Average Target
+67.01%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -35.46% | 641M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 6855 Stock
- Funds and ETFs Ascentage Pharma Group International
